share_log

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Brookline Capital Reiterates Buy on Adial Pharmaceuticals, Maintains $6 Price Target

Brookline Capital重申買入Adial Pharmicals,維持6美元的目標股價
Benzinga ·  2023/07/12 17:59

Brookline Capital analyst Kumaraguru Raja reiterates Adial Pharmaceuticals (NASDAQ:ADIL) with a Buy and maintains $6 price target.

Brookline Capital分析師Kumaraguru Raja重申了Adial Pharmicals(納斯達克股票代碼:ADIL)的買入,並維持6美元的目標股價。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論